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Abstract. Acute pancreatitis is a common condition with alcohol and gallstones being the most frequent etiologies. 
The aim of our study was to determine the prevalence of hyperlipidemia, its etiopathogenetic role and influence on 
outcomes in patients with acute pancreatitis.The study included 47 patients admitted to our clinic for acute 
pancreatitis during one year period. On admission patients with hyperlipidemia were compared to those without it, 
regarding following parameters: body mass index, Glasgow score, organ failure occurrence, local complications 
occurrence (pancreatic necrosis, pseudocyst, abscess, jaundice, gastric outlet syndrome), intensive care unit stay and 
death. The results of the study revealed high incidence of hyperlipidemia in 51% of examined acute pancreatitis patients 
with the prevalence of severe forms in more than half of these patients. Dominant lipid disorder was 
hypertriglyceridemia, followed by hypercholesterolemia. It was clearly demonstrated that patients with hyperlipidemia, 
especially hypertriglyceridemia, had more severe acute pancreatitis, higher incidence of complications and poorer 
outcome compared to normolipemic patients. Hyperlipidemia in patients with acute pancreatitis should be considered 
and treated by a clinician as a separate serious problem, both when being a cause and a concomitant disorder. 
Hypolipidemic therapy should be administered both in urgent acute pancreatitis settings and as a long-term treatment 
aimed to prevent inflammation recurrence by successful persistent serum lipid levels control. 
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Introduction

 
Acute pancreatitis (AP) represents a serious clinical 
issue in everyday surgical practice. Alcohol and gallstones 
are the most frequent etiologies of this potentially severe 
condition. Other causes, like metabolic, structural and 
iatrogenic, account for up to 25% of AP cases [1].  
Yadav and Pitchumoni [2] remarked that in 1846 Speck 
[3] was the first who described an association of the 
hyperlipidemia (HLP) and AP. However, since then 
etiological correlation of lipid disorders and AP still remains 
unclear. Hyperlipidemia may be an epiphenomenon to AP, 
since secondary lipid abnormalities are commonly found in 
patients with alcohol-induced AP and diabetic, pregnant 
and obese patients [4]. Nevertheless, primary lipid 
disorders, especially hypertriglyceridemia (HTG) or 
chylomicronemia, may independently induce AP and are 
responsible for up to 7% of cases [1]. Contrary to HTG, 
hypercholesterolemia does not cause AP [2]. Also, it is still 
uncertain whether HLP influences the evolution and 
outcome of AP. In available literature it has been suggested 
both that the presence of HLP is associated with more 
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severe forms of AP [5] and, alternatively, that it does not 
intensify the course of inflammatory disease [6]. Cameron 
et al. reported that association between lipid abnormalities 
and AP is more than coincidental stating that lipids may 
play an intermediary role in the pathogenesis of this 
disease [7]. 
The aim of our study was to determine the prevalence 
of HLP, its etiopathogenetic role and influence on 
outcomes in patients with AP. 
Material and Methods 
The data were collected prospectively and the study 
included patients admitted to our clinic for AP during 
one year period with serum amylase level two times 
higher than normal range (28–100 U/L) considered 
confirmatory [8]. Patients previously treated elsewhere 
for actual AP episode and those with exacerbated chronic 
pancreatitis and pre-existing organ failure were excluded. 
On admission complete laboratory investigation was 
performed and Body mass index (BMI) was calculated 
(kg/m2). Lipid status assessment was done within 24h 
of admission and included measurement of triglycerides 
(TG), cholesterol, low density (LDL) and very low density 
lipoproteins serum levels. Radiological “imaging” 
assessment included abdominal ultrasound within 48h 
of admission and multi-slice computed tomography 
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examination performed on the 6th day after disease 
onset. The aetiology of AP was ascertained from history 
and collected examination data and disease severity was 
assessed by the Glasgow criteria and the occurrence of 
organ dysfunction. Lipid status assessment was repeated 
on discharge and, if elevated on discharge, serum lipids 
were measured again one month after discharge. Patients 
were categorized according to Fredrickson classification 
of HLP.  
Patients with HLP on admission were compared to 
those without HLP regarding following parameters: 
BMI, Glasgow score (GS), organ failure occurence (OF), 
local complications (LC) occurrence (pancreatic necrosis, 
pseudocyst, abscess, jaundice, gastric outlet syndrome), 
intensive care unit (ICU) stay and lethal outcome (LO). 
The data were statistically analyzed using nonparametric 
Pearson’s chi-squared test. 
Results 
From January 2012 to January 2013 there were 47 
patients ― 29 (62%) males and 18 (38%) females with 
average age of 41 years (range, 19–76) admitted for AP. 
Alcohol was the cause in 25 (53%) and gallstones in 22 
(47%) patients. The incidence of potential additional 
etiological factors was as follows: two patients were 
taking thiazide diuretics, one estrogen contraceptive and 
one was on statins therapy, seven were diabetic. Six 
patients stated that one or both of their parents have had 
HLD, but were not able to provide precise data about 
the form of HLP, its duration, intensity and outcome, 
which (with inability to perform genetic investigation) 
was not enough to diagnose familial HLP. The incidence 
and distribution of hyperlipidemic disorders are presented 
in Table 1; the prevalence of examined parameters is 
presented in in the Figure 1. 
Table 1. The incidence and distribution of hyperlipidemic 
disorders 
Type of hyperlipidemia   No of patients: 24                     
Hypercholesterolemia  8 (33%) 
Moderate  3 
Severe  5 
Hypertriglyceridemia  16 (67%) 
Moderate  7 
Severe  9 
Transient (normalized at discharge)  11 (46%) 
Persistent (one month after discharge)  8 (33%) 
Lethal outcome  5 (21%) 
Out of 10 patients with GS>3 seven had HLP, out of 
10 patients with organ failure six had HLP, out of 17 
patients treated in ICU 12 had HLP, out of 14 patients 
with local complications 10 had HLP and out of six 
patients that died five had HLP (Fig. 2). 
The correlation between the duration of HLP (transient 
or persistent) and severity, course and outcome of AP is 
presented in the Figure 3. The analysis of correlation 
between the severity of HLP and severity, course and 
outcome of AP revealed similar pattern (Table 2). 
 
Fig. 1. The prevalence of examined parameters. 
 LO, lethal outcome; LC, local complications; ICU, intensive 
care unit treatment; OF, organ failure; GS, Glasgow score. 
 
Fig 2. Correlation between lipid status and severity, 
course and outcome of acute pancreatitis. 
HLP, patients with hyperlipidemia; NonHLP, patients 
without hyperlipidemia; GS, Glasgow score; OF, organ 
failure; ICU, intensive care unit treatment; LC, local 
complications; LO, lethal outcome. 
 
Fig. 3. The correlation between the duration of transient or 
persistent hyperlipidemia and severity, course and 
outcome of acute pancreatitis 
GS, Glasgow score; OF, organ failure; ICU, intensive 
care unit treatment; LC, local complications; LO, lethal 
outcome. 
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Discussion  
The results of our clinical study revealed high incidence of 
HLP in 51% of examined AP patients with the prevalence 
of severe forms in more than half of these patients. 
Dominant lipid disorder was HTG, followed by 
hypercholesterolemia. HTG is rare, but well documented 
cause of severe AP. In experimental model, infusion of 
triglycerides induces significant histopathological changes 
of pancreas tissue including oedema and hemorrhage, 
similar to AP [9]. Also, HLP deteriorates the course of 
experimental AP (both oedematous and necrotizing) [5, 
10], while in human population with the history of AP 
exogenous lipids intake induces HLP with acute abdominal 
pain [7]. Reportedly, HTG may cause respiratory failure in 
patients with AP [11]. The serum triglyceride level (STL) 
that may induce AP or significantly influence its severity 
and course is not strictly determined yet. As reported by 
some authors, HTG-induced AP rarely develops with STL 
lower than 20 mmol/L [6]. Nevertheless, some reports state 
that STL higher than 11.3 mmol/L may initiate AP episode 
and that its reduction prevents further inflammation 
episodes [12]. It has also been reported that HTG can 
increase the pancreas damage during AP and predispose 
the transition from oedematous to necrotizing AP if STL 
exceeds 5.65 mmol/L [13]. STL exceeds 20 mmol/L 
almost exclusively in patients with genetic lipid disorder 
(familial HTG) and in these patients the settings of AP 
may induce severe pain and lead to a state called 
“hyperlipidemic abdominal crisis”. 
HTG is considered the third most frequent cause of AP, 
after alcohol and gallstones [6, 12]. The incidence of lipid 
abnormalities in AP patients varies from 3.8 to 39% [6, 7]. 
However, secondary lipid metabolism disorders (especially 
mild to moderate) are most common in alcohol-induced 
AP and in diabetic, pregnant and obese patients [12]. 
However, in spite clear correlation, it may still be difficult 
to differentiate between mild to moderate HLP as 
secondary comorbidity in AP from severe HTG that 
primarily induces AP, particularly in patients with 
hereditary HLP. Also, the influence of HLP on AP 
evolution is still unclear, despite well documented 
association between high serum triglyceride levels and 
some molecular mechanisms of pancreas acinar cells 
damage. It has been reported that HTG independently 
influences the severity and deteriorates necrotizing AP [14, 
15]. On the other hand, some reports state that HLP 
does not influence the outcome of AP [2, 6, 16]. The 
results of our study clearly showed that patients with HLP, 
especially HTG, had more severe AP, higher incidence of 
complications and poorer outcome compared to 
normolipemic patients. Although this clearly indicates that 
HLP (HTG) worsened AP in our patients, it is reported 
that, in reverse, AP may induce HTG making this 
correlation a sort of a HTG-AP “circulus vitiosus” which 
may be difficult to cease [17]. 
Based on literature and our data from presented study, 
the administration of additional, specific hypolipidemic 
treatment (beside ordinary therapy for AP which is 
mandatory) would seem beneficial in patients with AP and 
HLP. Its goal would be maximal possible reduction of STL 
since it is reported that reduction of STL under 500 mg/dL 
[12], 1000 mg/dL [2] or 2000 mg/dL [18] may prevent 
abdominal pain and AP episode relapse. Although STL 
and serum chylomicrone levels rapidly decrease while 
fasting, targeted hypolipidemic therapy would accelerate 
plasma lipoproteins clearance. It is also well documented 
that dietary therapy combined with exercise and body 
weight loss facilitates the treatment and prevents 
inflammation relapse [2, 19]. The choice of hypolipidemic 
treatment is individual and depends on type and intensity 
of HLP and current disease/patient status. It includes many 
options, such as plasmapheresis, lipoprotein apheresis, 
insulin, heparin, purified apoC-II, penta-association 
therapy (hemofiltration and TG adsorption, statins and/or 
fibrates). However, despite the reasonable amount of 
evidence there is still a lack of agreement on routine use of 
these therapeutic variables. Nevertheless, many authors 
agree that maximal efforts should be made to prevent 
further hyperlipidemic AP episodes by achieving a 
permanent reduction of serum lipid levels using long-term 
medication (statins, fibrates, niacin), adequate dietary 
treatment (restriction of alcohol, fat and carbohydrate 
intake, enough antioxidants, vitamin, mineral and protein 
intake, fish oil supplements) and successful control of 
secondary aggravating factors and comorbidities (diabetes, 
obesity, hypothyroidism). 
Conclusion  
Since the incidence of HLP in patients with AP may be 
quite high, it should be considered and treated by a 
clinician as a separate serious problem, both when being 
a cause and a concomitant disorder. Hypolipidemic 
therapy should be administered both in urgent AP 
settings and as a long-term treatment aimed to prevent 
inflammation recurrence by successful persistent serum 
lipid levels control. 
Table 2. The incidence and distribution of hyperlipidemic disorders 
 Hypercholesterolemia 
Overall 
Hypertriglyceridemia 
 Moderate Severe Moderate Severe 
Glasgow score >3 0 2 2 : 5 2 3 
Organ failure 1 1 2 : 4 1 3 
Intensive care unit 1 3 4 : 8 3 5 
Local complications 1 3 4 : 6 2 4 
Lethal outcome 0 0 0 : 5 1 4 
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